A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis

British Journal of Dermatology

Volumn 139, Issue 1, 1998, Pages 88-95

  Koo, J ^a   Abrams, B ^b   Albrecht, G ^b   Altmeyer, P ^b   Bahmer, F A ^b   Belaich, S ^b   Berth Jones, J ^b   Bjerke, J R ^b   Bos, J D ^b   Braathen, L ^b   Burg, G ^b   Burrows, D ^b   Claudy, A ^b   Drake, L A ^b   Dubertret, L ^b   Engst, R ^b   Ettelt, M I ^b   Frenk, E ^b   Frosch, P J ^b   Ganslandt, J ^b   Goos, M ^b   Graham Brown, R A C ^b   Guilhou, J J ^b   Haustein, U F ^b   Helland, S ^b   Hutchinson, K ^b   Jacobi, H ^b   Jung, E G ^b   Kang, S ^b   Kind, P ^b   Knop, J ^b   Lowe, N J ^b   Luger, T ^b   Mahrle, G ^b   Marks, R ^b   Meffert, H ^b   Meyer, J ^b   Mork N J ^b   Mrowietz, U ^b   Neumann, H A M ^b   Olsen, E A ^b   Rogers, S ^b   Ruzicka, T ^b   Schmidt, A G ^b   Schopf E ^b   Shupack, J L ^b   Starink, T M ^b   Tio, D ^b   Van Vloten, W A ^b   Vermeer, B J ^b   Wollina, U ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GELATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADOLESCENT; ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS;

EID: 0031847245     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02319.x     Document Type: Article

References (12)

1. Mueller W, Herrmann B. Cyclosporine A for psoriasis. N Engl J Med 1979; 301: 555.
2. Ellis CN, Fradin MS, Messana JM et al. Cyclosporin for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84.
3. van Joost TH, Bos JD, Heule F et al. Low dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol 1988; 118: 183-90.
4. Ippolito F. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Dermatology 1993; 187: 19-29.
5. Faulds D, Goa KL, Benfield P, Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
6. Vonderscher J, Meinzer A. Cyclosporin advantages and limitations or rationale for the development of Sandimmun Neoral®. In: International Congress on Immunointervention: the Role of Neoral® in Immune-based Diseases. Rome: Blackwell Healthcare Communications, 1996: 21.
7. Elder CA, Moore M, Chang C-T et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865-75.
8. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis. Br J Dermatol 1996; 135: 775-7.
9. Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 1654-60.
10. Powles AV, Cook T, Hulme B et al. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1993; 128: 159-65.
11. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis. Br J Dermatol 1992; 126: 621-3.
12. Lowe NJ, Weider JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-19.